A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: October 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance Federal Update As of this writing, Congress has failed to come to an agreement on funding for the current fiscal year and the federal government is in a shutdown. We are closely monitoring the impact that the shutdown is having on the patient community and … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued
KVIA-TV ABC-7 Features OCRA-Funded Research Developing Nanotechnology for Ovarian Cancer Detection
KVIA-TV ABC-7 News El Paso recently spotlighted the groundbreaking work of OCRA-funded researcher Daniel Heller, PhD of Memorial Sloan Kettering Cancer Center, whose research lab is working to develop a liquid biopsy that uses nanotechnology and artificial intelligence (AI) to detect ovarian cancer earlier. We’re developing a liquid biopsy that uses nano sensors and AI … Continued